Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

Ophélie Champion, Sophie Maiga, Christelle Dousset, Agnès Aubry, Céline Bellanger, François Guillonneau, Jose Antonio Moreno, Ohyun Kwon, Philippe Moreau, David Chiron, Catherine Pellat-Deceunynck, Cyrille Touzeau, Patricia Gomez-Bougie

Blood (2024) 144 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2024-194462

Published: 2024

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Blood (2023) 142 (18): 1543–1555.

https://doi.org/10.1182/blood.2023020211

Published: 2023

Includes: Supplemental data

Journal Articles

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Salomé Decombis, Celine Bellanger, Yannick Le Bris, Delphine Boulet, Jane Jardine, Christelle Dousset, Audrey Ménard, Charlotte Kervoelen, Elise Douillard, Philippe Moreau, Stephane Minvielle, Agnes Moreau-Aubry, Benoit Tessoulin, Nicolas Bidère, Steven Le Gouill, Catherine Pellat-Deceunynck, David Chiron

Blood (2022) 140 (Supplement 1): 2044–2045.

https://doi.org/10.1182/blood-2022-157694

Published: 2022

Journal Articles

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 4198–4199.

https://doi.org/10.1182/blood-2022-155862

Published: 2022

Journal Articles

The IL32/BAFF Axis Supports Prosurvival Dialog in the Lymphoma Ecosystem and Is Disrupted By NIK Inhibition

Salome Decombis, Antonin Papin, Celine Bellanger, Clara Sortais, Christelle Dousset, Yannick Le Bris, Stephanie Blandin, Philippe Hulin, Benoit Tessoulin, Mathieu Rouel, Steven Le Gouill, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck, David Chiron

Blood (2021) 138 (Supplement 1): 781.

https://doi.org/10.1182/blood-2021-144839

Published: 2021

Journal Articles

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

David Chiron, Céline Bellanger, Antonin Papin, Benoit Tessoulin, Christelle Dousset, Sophie Maiga, Anne Moreau, Julie Esbelin, Valérie Trichet, Selina Chen-Kiang, Philippe Moreau, Cyrille Touzeau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2016) 128 (24): 2808–2818.

https://doi.org/10.1182/blood-2016-06-720490

Published: 2016

Includes: Supplemental data

Journal Articles

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

David Chiron, PhD, Celine Bellanger, Antonin Papin, Benoit Tessoulin, MD, Christelle Dousset, Sophie Maiga, Anne Moreau, MD, Julie Esbelin, MD, Valerie Trichet, PhD, Selina Chen-Kiang, PhD, Philippe Moreau, Cyrille Touzeau, MD, Steven Le Gouill, MD PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2016) 128 (22): 1096.

https://doi.org/10.1182/blood.V128.22.1096.1096

Published: 2016

Journal Articles

Mantle-Cell Lymphoma (MCL) Cells Are Highly Sensitive To ABT-199 But Their Sensitivity May Be Altered By The Microenvironment Via The Up-Regulation Of Bcl-Xl and Bcl2A1

Cyrille Touzeau, MD, Carole Brosseau, PhD, Christelle Dousset, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD, PhD, Martine Amiot, PhD

Blood (2013) 122 (21): 4285.

https://doi.org/10.1182/blood.V122.21.4285.4285

Published: 2013

Journal Articles

Vitamin D3 and Lenalidomide Synergize To Induce Apoptosis In Mantle Cell Lymphoma Via Demethylation Of BIK

Carole Brosseau, PhD, Christelle Dousset, Cyrille Touzeau, MD, Sophie Maiga, Philippe Moreau, MD, Martine Amiot, PhD, Steven Le Gouill, MD, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2013) 122 (21): 1830.

https://doi.org/10.1182/blood.V122.21.1830.1830

Published: 2013

Journal Articles

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Linda Bodet, Patricia Gomez-Bougie, Cyrille Touzeau, Christelle Dousset, Géraldine Descamps, Sophie Maïga, Hervé Avet-Loiseau, Régis Bataille, Philippe Moreau, Steven Le Gouill, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2011) 118 (14): 3901–3910.

https://doi.org/10.1182/blood-2010-11-317438

Published: 2011

Includes: Supplemental data

Journal Articles

Rational for the Use of a Targeted-Therapy Using ABT-737 In Mantle-Cell Lymphoma

Cyrille Touzeau, Christelle Dousset, Lynda Bodet, Stephanie Bonnaud, Patricia Gomez-Bougie, Thomas Gastinne, Soraya Wuilleme, Anne Moreau, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, Steven Le Gouill

Blood (2010) 116 (21): 770.

https://doi.org/10.1182/blood.V116.21.770.770

Published: 2010

Journal Articles

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Linda Bodet, Catherine Pellat-Deceunynck, PhD, Patricia Gomez-Bougie, PhD, Christelle Dousset, Cyrille Touzeau, Steven Le Gouill, MD, PhD, Hervé Avet-Loiseau, MD, PhD, Regis Bataille, MD, PhD, Martine Amiot, PhD

Blood (2010) 116 (21): 4061.

https://doi.org/10.1182/blood.V116.21.4061.4061

Published: 2010

NARROW

Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

The IL32/BAFF Axis Supports Prosurvival Dialog in the Lymphoma Ecosystem and Is Disrupted By NIK Inhibition

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial

Mantle-Cell Lymphoma (MCL) Cells Are Highly Sensitive To ABT-199 But Their Sensitivity May Be Altered By The Microenvironment Via The Up-Regulation Of Bcl-Xl and Bcl2A1

Vitamin D3 and Lenalidomide Synergize To Induce Apoptosis In Mantle Cell Lymphoma Via Demethylation Of BIK

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Rational for the Use of a Targeted-Therapy Using ABT-737 In Mantle-Cell Lymphoma

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only